BIOTRON LIMITED - Announcements

Market Cap $17.14M Add to my watchlist

Healthcare Biotechnology

Biotron Limited is an Australia-based biotechnology company. The Company is primarily... Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.More

Announcements

Filter Results

All Price Sensitive Only

BIT	Response to ASX Aware Query	PRICE SENSITIVE	25/09/24	1.5MB	Share
BIT	BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL	PRICE SENSITIVE	06/09/24	540.68KB	Share
BIT	Appendix 4G		30/08/24	264.8KB	Share
BIT	Corporate Governance Statement		30/08/24	216.37KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	30/08/24	1.41MB	Share
BIT	Application for quotation of securities - BIT		15/08/24	15.36KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	1.01MB	Share
BIT	Application for quotation of securities - BIT		22/07/24	15.35KB	Share
BIT	Letter to Shareholders		11/07/24	1006.55KB	Share
BIT	Webinar Investors Presentation		26/06/24	3.99MB	Share
BIT	BIOTRON CLINICAL TRIAL RESULTS WEBINAR		25/06/24	828.97KB	Share
BIT	BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives	PRICE SENSITIVE	19/06/24	711.16KB	Share
BIT	Change of Share Registry address		23/05/24	95.43KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/04/24	1MB	Share
BIT	POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV	PRICE SENSITIVE	05/04/24	670.99KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	27/03/24	453.67KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/24	603.88KB	Share
BIT	$1.64M R&D rebate received		08/02/24	269.89KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/24	277.88KB	Share
BIT	Shareholder Update		14/12/23	127.05KB	Share
BIT	Application for quotation of securities - BIT		01/12/23	24.61KB	Share
BIT	Change of Director's Interest Notice MM		27/11/23	197.97KB	Share
BIT	Notification of cessation of securities - BIT		27/11/23	21.45KB	Share
BIT	Results of AGM		22/11/23	92.59KB	Share
BIT	Presentation to Annual General Meeting		22/11/23	1.58MB	Share
BIT	Application for quotation of securities - BIT		10/11/23	24.66KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/23	1.03MB	Share
BIT	Application for quotation of securities - BIT		26/10/23	24.66KB	Share
BIT	Presentation to Investors		24/10/23	979.37KB	Share
BIT	Annual Report/Notice of Annual General Meeting/Proxy Form		20/10/23	1.33MB	Share
BIT	Application for quotation of securities - BIT		10/10/23	24.66KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	29/09/23	712.55KB	Share
BIT	Letter to Shareholders		26/09/23	373.27KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	11/09/23	665.15KB	Share
BIT	Appendix 4G		25/08/23	256.42KB	Share
BIT	Corporate Governance Statement		25/08/23	213.39KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	25/08/23	1.05MB	Share
BIT	COMPLETION OF PHASE 2 COVID CLINICAL TRIAL	PRICE SENSITIVE	16/08/23	312.28KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	475.77KB	Share
BIT	Second Site Approved for Phase 2 Covid-19 Trial	PRICE SENSITIVE	12/05/23	89.11KB	Share
BIT	Commencement Phase 2 Covid-19 Clinical Trial	PRICE SENSITIVE	04/05/23	144.72KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	1.01MB	Share
BIT	Cleansing Notice		22/03/23	99.09KB	Share
BIT	Application for quotation of securities - BIT		22/03/23	24.65KB	Share
BIT	Completion of Phase 2 HIV-1 Clinical Trials	PRICE SENSITIVE	09/03/23	403.58KB	Share
BIT	International Presentation of BIT225 COVID-19 Data	PRICE SENSITIVE	21/02/23	824.33KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	17/02/23	794.46KB	Share
BIT	Notification of cessation of securities - BIT		01/02/23	21.47KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	436.71KB	Share
BIT	CLEANSING NOTICE		25/01/23	262.54KB	Share
BIT	Application for quotation of securities - BIT		25/01/23	24.68KB	Share
BIT	Change of Director's Interest Notice		29/11/22	250.15KB	Share
BIT	Notification of cessation of securities - BIT		28/11/22	21.5KB	Share
BIT	Cleansing Notice		25/11/22	97.91KB	Share
BIT	Listed Options Information		25/11/22	98.9KB	Share
BIT	Application for quotation of securities		25/11/22	358.97KB	Share
BIT	Application for quotation of securities - BIT		25/11/22	29.22KB	Share
BIT	Proposed issue of securities - BIT		24/11/22	27.45KB	Share
BIT	Rights Issue Closed	PRICE SENSITIVE	24/11/22	174.24KB	Share
BIT	Supplementary Prospectus	PRICE SENSITIVE	24/11/22	139.65KB	Share
BIT	Cancel - Proposed issue of securities - BIT		22/11/22	38.86KB	Share
BIT	Appendix 3B		21/11/22	753.77KB	Share
BIT	$1.43M R&D rebate received	PRICE SENSITIVE	18/11/22	148.2KB	Share
BIT	Results of Annual General Meeting		16/11/22	173.02KB	Share
BIT	Chairman's Address and Presentation to AGM		16/11/22	370.97KB	Share
BIT	Presentation to Investors		11/11/22	408.74KB	Share
BIT	Clarification of Fractional Entitlements		07/11/22	112.37KB	Share
BIT	Commencement of Rights Trading - BITRC	PRICE SENSITIVE	31/10/22	128.29KB	Share
BIT	Letter to Shareholders		31/10/22	370.18KB	Share
BIT	Prospectus	PRICE SENSITIVE	27/10/22	683.43KB	Share
BIT	Renounceable Issue	PRICE SENSITIVE	27/10/22	190.28KB	Share
BIT	Proposed issue of securities - BIT		27/10/22	39.21KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/10/22	422.98KB	Share
BIT	Annual Report and Notice of Annual General Meeting		14/10/22	2.98MB	Share
BIT	Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	04/10/22	181.16KB	Share
BIT	Bit225 Covid-19 Human Study Commenced	PRICE SENSITIVE	14/09/22	175.41KB	Share
BIT	BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	23/08/22	154.11KB	Share
BIT	Appendix 4G and Corporate Governance Statement		19/08/22	638.34KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	19/08/22	670.98KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/22	1.04MB	Share
BIT	POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM	PRICE SENSITIVE	30/05/22	130.47KB	Share
BIT	BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS	PRICE SENSITIVE	02/05/22	353.01KB	Share
BIT	Quarterly Cash Flow Report Appendix 4C	PRICE SENSITIVE	26/04/22	250.36KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	26/04/22	137.32KB	Share
BIT	$1.56M R&D Rebate Received	PRICE SENSITIVE	05/04/22	147.99KB	Share
BIT	BIT225 Effectiveness Against COVID-19 in Animals	PRICE SENSITIVE	17/03/22	214.51KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/22	630.82KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	135.98KB	Share
BIT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	248.82KB	Share
BIT	Update on Biotron HIV-1 And COVID-19 Programs		16/12/21	406.87KB	Share
BIT	Notification of cessation of securities - BIT		06/12/21	21.5KB	Share
BIT	BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS	PRICE SENSITIVE	25/11/21	594.07KB	Share
BIT	Results of Meeting		23/11/21	159.5KB	Share
BIT	Chairman's Address and Presentation to AGM		23/11/21	482.81KB	Share
BIT	COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS	PRICE SENSITIVE	01/11/21	157.65KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	28/10/21	140.11KB	Share
BIT	Quarterly Cash Flow Report	PRICE SENSITIVE	28/10/21	155.44KB	Share
BIT	Annual Report and Notice of Annual General Meeting		20/10/21	2.79MB	Share
BIT	Full Year Statutory Accounts and Preliminary Final Report	PRICE SENSITIVE	27/08/21	951.58KB	Share
BIT	Appendix 4G and Corporate Governance Statement		27/08/21	677.29KB	Share

BIT Response to ASX Aware Query
25/09/24	PRICE SENSITIVE	1.5MB	Share
BIT BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL
06/09/24	PRICE SENSITIVE	540.68KB	Share
BIT Appendix 4G
30/08/24		264.8KB	Share
BIT Corporate Governance Statement
30/08/24		216.37KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
30/08/24	PRICE SENSITIVE	1.41MB	Share
BIT Application for quotation of securities - BIT
15/08/24		15.36KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	1.01MB	Share
BIT Application for quotation of securities - BIT
22/07/24		15.35KB	Share
BIT Letter to Shareholders
11/07/24		1006.55KB	Share
BIT Webinar Investors Presentation
26/06/24		3.99MB	Share
BIT BIOTRON CLINICAL TRIAL RESULTS WEBINAR
25/06/24		828.97KB	Share
BIT BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
19/06/24	PRICE SENSITIVE	711.16KB	Share
BIT Change of Share Registry address
23/05/24		95.43KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
26/04/24	PRICE SENSITIVE	1MB	Share
BIT POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV
05/04/24	PRICE SENSITIVE	670.99KB	Share
BIT Response to ASX Price Query
27/03/24	PRICE SENSITIVE	453.67KB	Share
BIT Half Yearly Report and Accounts
27/02/24	PRICE SENSITIVE	603.88KB	Share
BIT $1.64M R&D rebate received
08/02/24		269.89KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
30/01/24	PRICE SENSITIVE	277.88KB	Share
BIT Shareholder Update
14/12/23		127.05KB	Share
BIT Application for quotation of securities - BIT
01/12/23		24.61KB	Share
BIT Change of Director's Interest Notice MM
27/11/23		197.97KB	Share
BIT Notification of cessation of securities - BIT
27/11/23		21.45KB	Share
BIT Results of AGM
22/11/23		92.59KB	Share
BIT Presentation to Annual General Meeting
22/11/23		1.58MB	Share
BIT Application for quotation of securities - BIT
10/11/23		24.66KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
27/10/23	PRICE SENSITIVE	1.03MB	Share
BIT Application for quotation of securities - BIT
26/10/23		24.66KB	Share
BIT Presentation to Investors
24/10/23		979.37KB	Share
BIT Annual Report/Notice of Annual General Meeting/Proxy Form
20/10/23		1.33MB	Share
BIT Application for quotation of securities - BIT
10/10/23		24.66KB	Share
BIT Response to ASX Price Query
29/09/23	PRICE SENSITIVE	712.55KB	Share
BIT Letter to Shareholders
26/09/23		373.27KB	Share
BIT Response to ASX Price Query
11/09/23	PRICE SENSITIVE	665.15KB	Share
BIT Appendix 4G
25/08/23		256.42KB	Share
BIT Corporate Governance Statement
25/08/23		213.39KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
25/08/23	PRICE SENSITIVE	1.05MB	Share
BIT COMPLETION OF PHASE 2 COVID CLINICAL TRIAL
16/08/23	PRICE SENSITIVE	312.28KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	475.77KB	Share
BIT Second Site Approved for Phase 2 Covid-19 Trial
12/05/23	PRICE SENSITIVE	89.11KB	Share
BIT Commencement Phase 2 Covid-19 Clinical Trial
04/05/23	PRICE SENSITIVE	144.72KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	1.01MB	Share
BIT Cleansing Notice
22/03/23		99.09KB	Share
BIT Application for quotation of securities - BIT
22/03/23		24.65KB	Share
BIT Completion of Phase 2 HIV-1 Clinical Trials
09/03/23	PRICE SENSITIVE	403.58KB	Share
BIT International Presentation of BIT225 COVID-19 Data
21/02/23	PRICE SENSITIVE	824.33KB	Share
BIT Half Yearly Report and Accounts
17/02/23	PRICE SENSITIVE	794.46KB	Share
BIT Notification of cessation of securities - BIT
01/02/23		21.47KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	436.71KB	Share
BIT CLEANSING NOTICE
25/01/23		262.54KB	Share
BIT Application for quotation of securities - BIT
25/01/23		24.68KB	Share
BIT Change of Director's Interest Notice
29/11/22		250.15KB	Share
BIT Notification of cessation of securities - BIT
28/11/22		21.5KB	Share
BIT Cleansing Notice
25/11/22		97.91KB	Share
BIT Listed Options Information
25/11/22		98.9KB	Share
BIT Application for quotation of securities
25/11/22		358.97KB	Share
BIT Application for quotation of securities - BIT
25/11/22		29.22KB	Share
BIT Proposed issue of securities - BIT
24/11/22		27.45KB	Share
BIT Rights Issue Closed
24/11/22	PRICE SENSITIVE	174.24KB	Share
BIT Supplementary Prospectus
24/11/22	PRICE SENSITIVE	139.65KB	Share
BIT Cancel - Proposed issue of securities - BIT
22/11/22		38.86KB	Share
BIT Appendix 3B
21/11/22		753.77KB	Share
BIT $1.43M R&D rebate received
18/11/22	PRICE SENSITIVE	148.2KB	Share
BIT Results of Annual General Meeting
16/11/22		173.02KB	Share
BIT Chairman's Address and Presentation to AGM
16/11/22		370.97KB	Share
BIT Presentation to Investors
11/11/22		408.74KB	Share
BIT Clarification of Fractional Entitlements
07/11/22		112.37KB	Share
BIT Commencement of Rights Trading - BITRC
31/10/22	PRICE SENSITIVE	128.29KB	Share
BIT Letter to Shareholders
31/10/22		370.18KB	Share
BIT Prospectus
27/10/22	PRICE SENSITIVE	683.43KB	Share
BIT Renounceable Issue
27/10/22	PRICE SENSITIVE	190.28KB	Share
BIT Proposed issue of securities - BIT
27/10/22		39.21KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
24/10/22	PRICE SENSITIVE	422.98KB	Share
BIT Annual Report and Notice of Annual General Meeting
14/10/22		2.98MB	Share
BIT Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
04/10/22	PRICE SENSITIVE	181.16KB	Share
BIT Bit225 Covid-19 Human Study Commenced
14/09/22	PRICE SENSITIVE	175.41KB	Share
BIT BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
23/08/22	PRICE SENSITIVE	154.11KB	Share
BIT Appendix 4G and Corporate Governance Statement
19/08/22		638.34KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
19/08/22	PRICE SENSITIVE	670.98KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/22	PRICE SENSITIVE	1.04MB	Share
BIT POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
30/05/22	PRICE SENSITIVE	130.47KB	Share
BIT BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS
02/05/22	PRICE SENSITIVE	353.01KB	Share
BIT Quarterly Cash Flow Report Appendix 4C
26/04/22	PRICE SENSITIVE	250.36KB	Share
BIT Quarterly Activities Report
26/04/22	PRICE SENSITIVE	137.32KB	Share
BIT $1.56M R&D Rebate Received
05/04/22	PRICE SENSITIVE	147.99KB	Share
BIT BIT225 Effectiveness Against COVID-19 in Animals
17/03/22	PRICE SENSITIVE	214.51KB	Share
BIT Half Yearly Report and Accounts
23/02/22	PRICE SENSITIVE	630.82KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	135.98KB	Share
BIT Quarterly Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	248.82KB	Share
BIT Update on Biotron HIV-1 And COVID-19 Programs
16/12/21		406.87KB	Share
BIT Notification of cessation of securities - BIT
06/12/21		21.5KB	Share
BIT BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS
25/11/21	PRICE SENSITIVE	594.07KB	Share
BIT Results of Meeting
23/11/21		159.5KB	Share
BIT Chairman's Address and Presentation to AGM
23/11/21		482.81KB	Share
BIT COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS
01/11/21	PRICE SENSITIVE	157.65KB	Share
BIT Quarterly Activities Report
28/10/21	PRICE SENSITIVE	140.11KB	Share
BIT Quarterly Cash Flow Report
28/10/21	PRICE SENSITIVE	155.44KB	Share
BIT Annual Report and Notice of Annual General Meeting
20/10/21		2.79MB	Share
BIT Full Year Statutory Accounts and Preliminary Final Report
27/08/21	PRICE SENSITIVE	951.58KB	Share
BIT Appendix 4G and Corporate Governance Statement
27/08/21		677.29KB	Share

REFRESH

1 2 3 4 5

(20min delay)
Last 1.9¢		Change 0.000(0.00%)		Mkt cap ! $17.14M

Open	High	Low	Value	Volume
2.0¢	2.0¢	1.9¢	$3.921K	205.5K

Buyers (Bids)

No.	Vol.	Price($)
3	776274	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.0¢	1861030	4

View Market Depth

No.	Vol.	Price($)
3	776274	0.019
10	1774771	0.018
8	927388	0.017
12	3734154	0.016
10	1205000	0.015

Price($)	Vol.	No.
0.020	1861030	4
0.021	553409	2
0.022	997769	4
0.023	1449422	4
0.024	153949	2

Last trade - 16.10pm 01/10/2024 (20 minute delay)


Last 2.0¢		Change 0.000 ( 2.63 %)
Open	High	Low	Volume
2.0¢	2.0¢	1.9¢	385004
Last updated 13.23pm 01/10/2024 ?

BIT (ASX) Chart

BIOTRON LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories